Rare Cancer Research Foundation的动态

Feeder-free Natural Killer (NK) cell expansion systems are a desirable choice for clinical applications due to reduced safety risks. However, historically lower expansion rates of these systems present a challenge to widespread clinical adoption and are a key reason why feeder-based expansion systems are still frequently used, despite safety and regulatory risks. Check out Theragent's latest research, led by Raymond Wu Ph.D., on an innovative NK cell therapy solution that can help overcome this barrier. https://lnkd.in/gYQj2mDJ #CAGT #NKCELL #THERAGENT

What makes γδ2 T cells attractive candidates? - off-the-shelf cell therapy - have characteristics of both innate as well as adaptive immune systems - have the ability to travel distinct tissues for targeted treatment - But also coordinate a broader spectrum of anti-tumor activities by recruiting other immune cells and factors.

CD5 deletion enhances the antitumor activity of adoptive T cell therapies https://lnkd.in/eXbYNZCN

At Theragent Inc, we constantly are researching and testing new methods to help deliver the therapeutics of tomorrow to patients in need of them today. Download our latest white paper to see how we are driving new methods to generate NK cells using a feeder-free platform with reduced risks. #NKcells #CGT #CDMO #whitepaper

Adaptimmune announced that #FDA has granted accelerated approval to #TECELRA (#afamitresgene #autoleucel), a novel engineered #celltherapy for treating adults with advanced synovial #sarcoma. This marks the first time a cell therapy has been approved for a #solidtumor, offering an effective treatment option for patients with limited alternatives following prior #chemotherapy. This historical approval was based on the SPEARHEAD-1 trial, published in The Lancet, which achieved a 43% overall response rate with a median response duration of 6 months. https://lnkd.in/eDrdMUB5

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis https://lnkd.in/eYYR2Edh

Combining Harmone treatment with cell cycle inhibitors

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis https://lnkd.in/eYYR2Edh

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis https://lnkd.in/eYYR2Edh

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis https://lnkd.in/eYYR2Edh